• Publications
  • Influence
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.
CONTEXT Approximately half of patients with overt congestive heart failure (CHF) have diastolic dysfunction without reduced ejection fraction (EF). Yet, the prevalence of diastolic dysfunction andExpand
  • 1,803
  • 40
  • PDF
Plasma brain natriuretic peptide concentration: impact of age and gender.
OBJECTIVES We wished to examine the effects of age and gender on plasma brain natriuretic peptide (BNP) concentration in a population-based study. BACKGROUND Measurement of BNP concentration isExpand
  • 1,023
  • 28
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
CONTEXT Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure. OBJECTIVE To investigate the effects ofExpand
  • 1,341
  • 23
  • PDF
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.
Hypertension and heart failure (HF) are common diseases that, despite advances in medical therapy, continue to be associated with high morbidity and mortality. Therefore, innovative therapeuticExpand
  • 188
  • 18
  • PDF
Assessing the Travel-Related Behaviors of the Mobility-Disabled Consumer
Few consumer groups have greater potential and are more ignored than the disabled. Consisting of 50 million individuals in the United States, with discretionary income of over $200 billion, thisExpand
  • 222
  • 17
A Strategic Approach to Managing Crises.
Abstract This article encorporates the management literature on crisis to create a model that can be used to assess the seriousness of crisis. In addition, the model is extended for use by publicExpand
  • 182
  • 17
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
CONTEXT Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promiseExpand
  • 744
  • 15
  • PDF
RNA-based therapeutics: current progress and future prospects.
Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human diseases. This holds true for dozens of RNA-based therapeutics currently under clinicalExpand
  • 676
  • 15
  • PDF